Charles River Labs (CRL) Tops Q2 EPS by 10c; Boosts FY11 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q2 EPS of $0.70, ex-items, $0.10 better than the analyst estimate of $0.60. Revenue for the quarter came in at $288.3 million versus the consensus estimate of $287.9 million.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.